This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05980000
Recruitment Status : Recruiting
First Posted : August 7, 2023
Last Update Posted : January 30, 2024
Eli Lilly and Company
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2028
Estimated Study Completion Date : April 30, 2031